Kura Spins Out Diabetes Unit With $50M From Eli Lilly, BVF
KURA sits 72% above its 52-week low of $7.358.
Summary
Kura Oncology launched Caspian Therapeutics, a separately financed subsidiary focused on menin inhibitors for diabetes, with a $50 million financing led by BVF Partners and including Eli Lilly. Kura retains approximately half ownership and board representation, while Caspian takes over KO-7246 and related IP. Preclinical data showing beta-cell regeneration and improved glycemic control will be presented at EASD on September 29. This structure lets Kura keep its oncology focus while shareholders retain meaningful upside in a potentially disease-modifying diabetes program. The financing syndicate's quality—especially Lilly's participation—adds external validation to the science. Watch for the EASD presentation and Caspian's IND submission timing.
At the time of this announcement, KURA was trading at $12.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $7.36 to $13.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.